Adolor Corporation Announces Completion of Acquisition of Full Ownership
of ENTEREG(R) (alvimopan) - MarketWatch





Bulletin

Get news bulletins by email &raquo; U.S. stocks sharply lower as NYSE
invokes &#39;Rule 48&#39; for Tuesday&#39;s open







Sign in

Become a MarketWatch member today


* Front Page
* News Viewer
* Commentary
* Markets
* Investing
* Personal Finance
* Community
* Games














press release

Sept. 6, 2011, 8:00 a.m. EDT


Adolor Corporation Announces Completion of Acquisition of Full Ownership
of ENTEREG(R) (alvimopan)














EXTON, Pa., Sep 06, 2011 (BUSINESS WIRE) -- Adolor Corporation
(nasdaqgm:ADLR) today announced that it has completed its reacquisition
from GlaxoSmithKline (GSK) of all rights to Adolor's FDA-approved product
ENTEREG(R) (alvimopan).

"With GSK's assistance, we are well-positioned for a smooth and timely
transition of all ENTEREG-related efforts to Adolor, as planned," said
Michael D. Adelman, Vice President, Marketing and Sales. "We have
completed the expansion of our field sales force and our representatives
are in the field calling on customers. We have extensive knowledge of
this marketplace, and are excited to continue supporting Health Care
Provider efforts to accelerate patients' gastrointestinal recovery and
hospital discharge following bowel resection surgery."

About ENTEREG

Adolor markets and sells ENTEREG in the United States. ENTEREG is
indicated to accelerate the time to upper and lower gastrointestinal
recovery following partial large or small bowel resection surgery with
primary anastomosis. ENTEREG is available only for short-term (15 doses)
use in hospitalized patients. Only hospitals that have registered in and
met all of the requirements for the ENTEREG Access Support and Education
(E.A.S.E.) program may use ENTEREG. For more information on ENTEREG,
including its full prescribing information, the Boxed Warning regarding
short-term hospital use and the E.A.S.E.(R) Program, visit
www.ENTEREG.com .

About Adolor

Adolor Corporation is a biopharmaceutical company specializing in the
discovery, development and commercialization of novel prescription pain
and pain management products.

The Company's lead development program compound is ADL5945, a novel mu
opioid receptor antagonist being developed for chronic OIC that
demonstrated positive results in Phase 2 trials. The Company also has
several earlier-stage compounds under development for the management of
pain and CNS disorders.

For more information, visit www.adolor.com .

Forward-Looking Statements

This press release, and oral statements made with respect to information
contained in this release, may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements provide Adolor's current expectations or
forecasts of future events. These may include statements regarding market
prospects for ENTEREG; the development of potential pharmaceutical
products, including ADL5945; interpretation of clinical results;
prospects for regulatory approvals; anticipated scientific progress on
Adolor's research programs; and other statements regarding matters that
are not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as "anticipate,"
"estimate," "expect," "project," "intend," "plan," "believe" or other
words and terms of similar meaning or that otherwise express
contingencies, goals, targets or future development. These statements are
based upon management's current expectations and are subject to risks and
uncertainties, known and unknown, that could cause actual results and
developments to differ materially from those expressed or implied in such
statements due to general financial, economic, regulatory and political
conditions affecting the biotechnology and pharmaceutical industries, as
well as more specific risks and uncertainties facing Adolor such as those
set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Adolor urges you to carefully review
and consider the disclosures found in its filings which are available at
www.sec.gov and from Adolor at www.adolor.com . Given the uncertainties
affecting pharmaceutical companies such as Adolor, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you
should not rely on any such factors or forward-looking statements. Adolor
undertakes no obligation to publicly update or revise the statements made
herein or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise, except as may be required
by law.

This press release is available on the website http://www.adolor.com .

SOURCE: Adolor Corporation




        
        Adolor Corporation 
        Stephen W. Webster, 484-595-1500
        




Copyright Business Wire 2011


























Most Popular


1. 




2. 




3. 




4. 




5. 







Find a Broker


Ã‚Â»

















Featured Stories


* U.S. stock futures drop; Swiss franc slumps


* 
* Why the young jobless will ruin your portfolio

  Without jobs or accumulated wealth todayÃ¢Â€Â™s young Americans
  wonÃ¢Â€Â™t be able to retire, and those retiring soon...


* What to buy and what to avoid for the rest of 2011

  After this summerÃ¢Â€Â™s volatile sell-off, lower earnings expectations
  are already priced into stocks across...


* Dow headed below 10,000 as cyclical bear begins

  Technical pattern on the Dow Jones Industrial Average suggests the
  stock market has unfinished business to...














* WSJ
  o WSJ

* MarketWatch
  o MarketWatch
  o Facebook
  o Twitter





* Barron's
  o Barron's

* SmartMoney
  o SmartMoney

* AllThingsDigital
  o AllThingsDigital

* FINS
  o FINS

* More
  o BigCharts
  o Virtual Stock Exchange
  o Financial News
  o WSJ Asia
    - WSJ India
    - 
    - 

  o WSJ Europe
  o WSJ Americas
    - en Espa&ntilde;ol
    - em Portugu&ecirc;s

  o WSJ Radio
  o WSJ Wine





SEARCH








9:40 AM EDT

September 6, 2011


/marketstate/country/us
New York

Open


/marketstate/country/uk
London

Open


/marketstate/country/jp
Tokyo

Closed






/marketstate/country/us



/marketstate/country/uk



/marketstate/country/jp













View All


Latest News


1. /news/latest 9:40a

   Techs slide in broad market decline

2. 9:38a

   Newmont Mining up 2%, best on S&amp;P 500

3. 9:37a

   BREAKING

   U.S. stocks open sharply lower; Rule 48 invoked

4. 9:35a

   Marathon Oil shares drop 6.7% in early trade

5. 9:34a

   Harley-Davidson shares fall 7.8%, worst on S&amp;P 500

6. 9:32a

   BREAKING

   U.S. stocks open sharply lower; Rule 48 invoked

7. 9:29a

   CFPB nominee says he doesn&#39;t favor lawsuits

8. 9:23a

   Swiss escalation of currency wars to boost gold

9. 9:11a

   When using cash is better than credit

10. 9:11a

    Coming up: ISM services for August

11. 9:09a

    Treasurys up; 10-year yields hit record low

12. 9:00a

    What to buy and what to avoid for the rest of 2011

13. 8:59a

    Private-equity group Carlyle files for IPO

14. 8:55a

    U.S. stock futures drop; Swiss franc slumps

15. 8:51a

    European markets turn lower amid sovereign fears

16. 8:49a

    Europe, SNB in the spotlight

17. 8:48a

    PepsiCo, NFL renew &quot;multi-year&quot; sponsorship deal

18. 8:44a

    Why the young jobless will ruin your portfolio

19. 8:44a

    TuesdayÃ¢Â€Â™s biggest gaining &amp; declining stocks

20. 8:43a

    Italy budget backtrack stirs market worries

21. Loading more headlines...





dow


/quotes/zigman/627449/delayed
10,977.03


-263.23

-2.34%








nasdaq


/quotes/zigman/123127
2,427.40


-52.93

-2.13%








s&amp;p 500


/quotes/zigman/3870025
1,145.00


-28.97

-2.47%














Kiosk


* 1309316400000

  1309377600000



  Commodities Corner




  Myra P. Saefong
  Benching a benchmark Ã‚Â 
  West Texas Intermediate, the oil index long used to project U.S.
  motor-fuel price trends, no longer is accurate benchmark. Here's what's
  replaced it.


  /conga/kiosk/commentary3.html 166051



* 1309982400000

  1310072100000



  Tech Investor




  John Shinal
  Learning the lesson of tech jobs
  There are larger implications for the U.S. economy to be found in the
  hiring trends in the domestic tech sector, and in India.


  /conga/kiosk/commentary.html 166049



* 1309370400000

  1309428000000



  Second Opinion




  John C. Dvorak
  Dell can dominate PC world
  This is the perfect opportunity to wrest control of the U.S. PC
  business from Apple and H-P, and take over in China as well. All Dell
  has to do is execute.


  /conga/kiosk/wildcard4.html 166054



* 1241971200000

  1242619200000



  Weekend Investor




  The fine art of investing
  As an asset class, fine art is a proven long-term store of wealth. The
  current marketÃ‚Â  woes just add to art's allure.


  /conga/kiosk/investing.html 166124



* 1308830400000

  1308901200000



  Asia




  Rich tastes get pricier
  The cost of living the luxury life in Asia soared in dollar terms over
  the past year, according to a lifestyle index. What's behind the higher
  luxury prices?


  /conga/kiosk/wildcard2.html 165868



* 1303590000000

  1303749600000



  Car Review




  2012 VW Beetle Turbo
  It may resemble the "New Beetle,"Ã‚Â  but Volkswagen's 2012 offering is
  a better bug, writes Ron Amadon.
  Ã¢Â€Â¢ More car reviews from Ron Amadon


  165998



* 1247536800000

  1247587200000



  The Economy


  Ã‚Â 

  A moribund jobs market
  Data showed the U.S. economy still struggling to create jobs with
  payrolls creation flat, hourly earnings falling, and grim
  African-American jobless rates.


  /conga/kiosk/economy-politics.html 165896













MarketWatch.com

* Site Index
* Topics
* Help
* Feedback
* Newsroom Roster
* Media Archive
* Premium Products
* Mobile

* Company Info
* Code of Conduct
* Corrections
* Advertising Media Kit
* Advertise Locally
* License our Content
* Broker Center

* MarketWatch on Facebook
* 
* MarketWatch on Twitter
* 
* RSS
* Podcasts



* WSJ.com
* Barron's Online
* BigCharts
* Virtual Stock Exchange
* All Things Digital

* MarketWatch Community
* Financial News Online
* WSJ.com Small Business
* FINS: Finance, IT jobs, Sales jobs









Copyright © 2011 MarketWatch, Inc. All rights reserved.
By using this site, you agree to the Terms of Service and Privacy Policy.



Intraday Data provided by SIX Telekurs and subject to terms of use.
Historical and current end-of-day data provided by SIX Telekurs. Intraday
data delayed per exchange requirements. Dow Jones Indexes (SM) from Dow
Jones & Company, Inc. All quotes are in local exchange time. Real time
last sale data provided by NASDAQ. More information on NASDAQ traded
symbols and their current financial status. Intraday data delayed 15
minutes for Nasdaq, and 20 minutes for other exchanges. Dow Jones
IndexesSM from Dow Jones & Company, Inc. SEHK intraday data is provided
by SIX Telekurs and is at least 60-minutes delayed. All quotes are in
local exchange time.







* MarketsMarkets







  Data is loading...




* QuotesQuotes







  Data is loading...




* My PortfolioMy Portfolio







  Data is loading...




* My AlertsMy Alerts







  Data is loading...




* CommunityCommunity




  HOT PICKS MY PICKS MY GROUPS




  Data is loading...





ALERT:




MarketWatch Top Stories
Link to MarketWatch's Slice. 15







Email address or display name


Password




Remember me

Forgot password?






The action you requested requires a MarketWatch Community display name.




Sign In


Email address or display name


Password




Remember me

Forgot password?



Community

Get your FREE membership now Ã‚Â»

MarketWatch Community is a free service that lets you discover, organize
and share MarketWatch stories with other readers.

Learn More Ã‚Â»





The action you requested is only available to MarketWatch members.
Please sign in or register.




Sign In


Email address or display name


Password




Remember me

Forgot password?




Register

Don't have a MarketWatch account?

Get your FREE membership now Ã‚Â»


By registering, you are agreeing to MarketWatch's Terms of Service and to
receiving periodic news and special offers via email about MarketWatch
enhancements, products and services.



